Phenotypic characteristics of thymic B lymphocytes in myasthenia gravis

Modeling the intrathymic pathogenesis of myasthenia gravis

Myasthenia gravis is (MG) a prototypic autoimmune disease; the immune effector mechanisms and autoantigenic target have been delineated. However, the events that lead to the abrogation of self-tolerance to neuromuscular acetylcholine receptors (nAChRs) remain a mystery. The thymus gland has long been considered to hold the key to solving this mystery, although the nature of its involvement remains to be elucidated. The nAChR was one of the first self-proteins associated with a defined autoimmune disease that was found to be expressed on thymic stromal populations. The studies described herein represent our efforts to determine how this "promiscuous" autoantigen expression may be involved in the immunopathogenesis of MG. We review our work, characterizing the expression of the nAChR alpha subunit in the thymus, and advance a hypothesis and experimental model, which explore how intrathymic expression of this autoantigen may contribute to the immunopathogenesis of this autoimmune disease.

Pokeweed mitogen-induced immunoglobulin secretory responses of thymic B cells in myasthenia gravis: selective secretion of IgG versus IgM cannot be explained by helper functions of thymic T cells

The thymus, with its striking B cell infiltrates, is widely regarded as an important element in the pathogenesis of myasthenia gravis (MG) but its role remains to be elucidated. To gain further insight into the functional properties of MG thymic B cells, we studied the heavy chain isotype of immunoglobulin they produced in vitro in response to the T cell-dependent polyclonal activator pokeweed mitogen (PWM). MG thymic cells secreted prominent amounts of IgG but little IgM. In contrast, peripheral blood mononuclear cells (PBM) of the same subjects secreted similar amounts of IgG and IgM as did PBM of control subjects. In cell admixture experiments, MG thymic T cells, like PBM T cells, helped autologous PBM B cells produce IgM as well as IgG, although the overall magnitude of help for both isotypes appeared less than that of PBM T cells. Thus, in response to PWM, MG thymic B cells are largely committed to an IgG response and this likely reflects the intrinsic properties of these cells rather than the immunoregulatory properties of thymic T cells. This IgG isotype switch likely reflects in vivo activation events.

Theoretical mechanisms by which immunoglobulin therapy might benefit myasthenia gravis

The mechanisms underlying any clinical improvement observed in some patients with myasthenia gravis (MG) treated with normal immunoglobulin (Ig) are not defined. The pathologic alterations in the postsynaptic motor end plate in MG are likely due at least in part to one or more actions of antibodies against epitopes on the nicotinic acetylcholine receptor (anti-AChR Ab). Such anti-AChR Ab are secreted by B lymphocytes and are increased in the serum of MG patients but not of controls. The stimulus for anti-AChR Ab production in MG is unknown with evidence for a role of thymic abnormalities, immunoregulatory disturbances, and some possible molecular mimicry of exogenous antigens (microbial?). Postulated mechanisms underlying Ig effects in MG include: (i) competing with anti-AChR for binding to AChR; (ii) preventing attachment of Fc receptor-positive inflammatory cells to the anti-AChR Ab bound to the motor end plate; (iii) decreasing synthesis of anti-AChR Ab; and (iv) exerting an anti-idiotypic effect. Evidence for these mechanisms are discussed.